ライフサイエンスコーパス: chronic hepatitis

1 arcinoma (HCC) develops on the background of chronic hepatitis.

2 ymphocyte positioning in liver tissue during chronic hepatitis.

3 BACKGROUND & AIMS: Chronic hepatitis affects phenotypes of innate and adapt

4 itis E virus (HEV) has emerged as a cause of chronic hepatitis among immunocompromised patients.

5 ontrols with benign liver diseases including chronic hepatitis and compensated liver cirrhosis.

6 HCV infection causes approximately 70% of chronic hepatitis and is frequently associated with prim

7 Autoimmune hepatitis causes chronic hepatitis and often leads to cirrhosis and death

8 sponse to antiviral therapy in patients with chronic hepatitis B (CHB) , and to assess if these miRNA

9 129 with chronic hepatitis C (CHC), 555 with chronic hepatitis B (CHB) and 488 with non-alcoholic fat

10 elated liver cirrhosis and 115 patients with chronic hepatitis B (CHB) before and after 48 weeks of a

11 of oral nucleos(t)ide analogs (NAs) to treat chronic hepatitis B (CHB) brings about safety data in a

12 Chronic hepatitis B (CHB) exhibits a variety of clinical

13 Chronic hepatitis B (CHB) has become a treatable and con

14 M) treatment has been commonly used to treat Chronic Hepatitis B (CHB) in Asian countries based on TC

15 The natural course of chronic hepatitis B (CHB) infection and treatment respon

16 has been difficult to study in patients with chronic hepatitis B (CHB) infection.

17 r cirrhosis and/or hepatocellular carcinoma, chronic hepatitis B (CHB) is a major health problem.

18 Chronic hepatitis B (CHB) is characterized by hepatic in

19 y of interferon alpha (IFNalpha) therapy for chronic hepatitis B (CHB) patients is about 40% and ofte

20 that the responses to IFN-alpha treatment of chronic hepatitis B (CHB) patients is influenced by IFN-

21 rial, hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients with compensated live

22 Th9 and Th17 cells were quantified in chronic hepatitis B (CHB) patients with hepatic fibrosis

23 V DNA levels for inactive carrier status and chronic hepatitis B (CHB) progression in a community-bas

24 Patients with chronic hepatitis B (CHB) usually acquire the virus peri

25 Globally, one third of prevalent chronic hepatitis B (CHB) virus infection (HBV) occurred

26 The clinical role of STAT3 in chronic hepatitis B (CHB) was also investigated.

27 Treatment of patients with chronic hepatitis B (CHB) with nucleos(t)ide analogues (

28 In chronic hepatitis B (CHB), failure to control hepatitis

29 The incidences of chronic hepatitis B (CHB), Hepatitis B virus (HBV)-assoc

30 t)ide analog (NA) treatment in patients with chronic hepatitis B (CHB).

31 ctive factors against disease progression in chronic hepatitis B (CHB).

32 ndependent risk factor of liver cirrhosis in chronic hepatitis B (CHB).

33 tory responses can define clinical stages of chronic hepatitis B (CHB).

34 role in control of viral replication during chronic hepatitis B (cHBV) infection, but little is know

35 Patients with chronic hepatitis B (HBV DNA load, >17 000 IU/mL) were t

36 Chronic hepatitis B affects over 300 million people who

37 ent hepatitis B recurrence for patients with chronic hepatitis B after liver transplantation.

38 s to achieve a 90% reduction in new cases of chronic hepatitis B and C and a 65% reduction in mortali

39 Approximately 40% of chronic hepatitis B and C patients are susceptible to or

40 We identified chronic hepatitis B and C patients with healthcare utili

41 r reimbursed treatment) received therapy for chronic hepatitis B and C, respectively, by 2011.

42 in serum samples from patients with acute vs chronic hepatitis B and controls.

43 Chronic hepatitis B and D infections are major causes of

44 ing uninfected pregnant women, patients with chronic hepatitis B and D virus (HBV/HDV) infection, and

45 r carcinoma (HCC) and current treatments for chronic hepatitis B and HCC are suboptimal.

46 global burden of viral hepatitis, especially chronic hepatitis B and hepatitis C virus infections.

47 o reveal the molecular basis associated with chronic hepatitis B and IFN-alpha (IFNalpha) treatment r

48 elated to treatment outcome in patients with chronic hepatitis B are currently unknown.

49 ee of fibrosis, end-stage liver disease, and chronic hepatitis B at baseline (n = 485) were included.

50 TDF-treated patients with chronic hepatitis B have reduced bone mineral density, b

51 Chronic hepatitis B infection (HBV) is major cause of mo

52 Chronic hepatitis B infection affects >300 million peopl

53 among a national cohort of US veterans with chronic hepatitis B infection and examine risk factors f

54 ation useful for management of patients with chronic hepatitis B infection.

55 ope for treating adolescents and adults with chronic hepatitis B infection.

56 Current approaches to treatment for chronic hepatitis B involve suppression of hepatitis B v

57 Chronic hepatitis B is a serious liver disease and puts

58 ned the long-term outcome of 265 consecutive chronic hepatitis B liver transplant recipients treated

59 he introduction of these novel compounds for chronic hepatitis B necessitates a standardized appraisa

60 l chronic inflammatory liver diseases, e.g., chronic hepatitis B or C viral infection and steatohepat

61 symptoms), and without known HIV infection, chronic hepatitis B or C virus infection, or any conditi

62 symptoms), and without known HIV infection, chronic hepatitis B or C virus infection, or any conditi

63 superinfection and sequelae in patients with chronic hepatitis B or C.

64 rom patients with acute hepatitis B, but not chronic hepatitis B or controls, hepatocytes expressed A

65 ff-treatment nucleos(t)ide analogues (NA) in chronic hepatitis B patients (CHB) is unclear.

66 Among 2338 chronic hepatitis B patients followed during 2006-2013 i

67 hepatocellular carcinoma (HCC) incidence in chronic hepatitis B patients under long-term therapy wit

68 lone without hepatitis B immune globulin for chronic hepatitis B patients with preexisting lamivudine

69 Fifty-seven consecutive chronic hepatitis B patients with preexisting rt204 LAM-

70 cohort study included 1,951 adult Caucasian chronic hepatitis B patients without HCC at baseline who

71 Among 1635 chronic hepatitis B patients, 978 (59.8%) were immune or

72 eyond year 5 of ETV/TDF therapy in Caucasian chronic hepatitis B patients, particularly in those with

73 i-fibrotic activity compared with those from chronic hepatitis B patients, which were mainly mediated

74 ersons vaccinated in infancy, an analysis of chronic hepatitis B prevalence in racial and ethnic popu

75 he majority of persons currently treated for chronic hepatitis B require long-term or lifelong therap

76 ha (IFN-alpha) is an approved medication for chronic hepatitis B therapy.

77 Most individuals with chronic hepatitis B viral (HBV) infection acquired the i

78 Chronic hepatitis B viral (HBV) infection remains a sign

79 is a clinical indicator of poor outcome for chronic hepatitis B viral (HBV) infection.

80 Whether chronic hepatitis B virus (HBV) and hepatitis C virus (H

81 Chronic hepatitis B virus (HBV) infection affects 240 mi

82 d in antiviral treatment-naive patients with chronic hepatitis B virus (HBV) infection but not in tre

83 ference (RNAi)-based therapeutic ARC-520 for chronic hepatitis B virus (HBV) infection consists of a

84 he two drugs in patients with HBeAg-negative chronic hepatitis B virus (HBV) infection in a non-infer

85 he two drugs in patients with HBeAg-positive chronic hepatitis B virus (HBV) infection in a non-infer

86 rs associated with diabetes in patients with chronic hepatitis B virus (HBV) infection in North Ameri

87 The number of persons with chronic hepatitis B virus (HBV) infection in the United

88 Chronic hepatitis B virus (HBV) infection is a common ca

89 Chronic hepatitis B virus (HBV) infection is a global pu

90 Chronic hepatitis B virus (HBV) infection is a global pu

91 Chronic hepatitis B virus (HBV) infection is a major fac

92 Chronic hepatitis B virus (HBV) infection is a major glo

93 Chronic hepatitis B virus (HBV) infection is a major ris

94 Chronic hepatitis B virus (HBV) infection is a major ris

95 Chronic hepatitis B virus (HBV) infection is estimated t

96 Chronic Hepatitis B Virus (HBV) infection is generally n

97 Chronic hepatitis B virus (HBV) infection is partly resp

98 Chronic hepatitis B virus (HBV) infection is prevalent,

99 A hallmark of chronic hepatitis B virus (HBV) infection is the functio

100 Chronic hepatitis B virus (HBV) infection often develop

101 The heterogeneous clinical courses of chronic hepatitis B virus (HBV) infection reflect the co

102 Chronic hepatitis B virus (HBV) infection remains the mo

103 Vaccine failure with chronic hepatitis B virus (HBV) infection still develops

104 ican nations have among the highest rates of chronic hepatitis B virus (HBV) infection worldwide, but

105 ms that govern distinct clinical phases of a chronic hepatitis B virus (HBV) infection-immune toleran

106 nfections and are particularly promising for chronic hepatitis B virus (HBV) infection.

107 ear from the liver diseases that result from chronic hepatitis B virus (HBV) infection.

108 unomodulatory effect are rarely addressed in chronic hepatitis B virus (HBV) infection.

109 titis B surface Ag (HBsAg) seroconversion in chronic hepatitis B virus (HBV) infection.

110 lular carcinoma (HCC), often associated with chronic hepatitis B virus (HBV) infection.

111 and linkage to care can reduce the burden of chronic hepatitis B virus (HBV) infection.

112 rn of hepatitis B surface antigen (HBsAg) in chronic hepatitis B virus (HBV) infections of China rema

113 rsion represents an endpoint of treatment of chronic hepatitis B virus (HBV) infections.

114 ) in low-replicative (HBV DNA <20,000 IU/mL) chronic hepatitis B virus (HBV) patients.

115 ediated disturbance of Mg(2+) homeostasis on chronic hepatitis B virus (HBV)-infected natural killer

116 onse is compatible with acute, resolved, and chronic hepatitis B virus (HBV)infection but might also

117 Chronic hepatitis B virus carriers are at risk of develo

118 European guidelines recommend treatment of chronic hepatitis B virus infection (CHB) with the nucle

119 Chronic hepatitis B virus infection is a leading cause o

120 Chronic hepatitis B virus or hepatitis C co-infection wa

121 ne samples from HBeAg-positive patients with chronic hepatitis B were analyzed.

122 Differences between patients with chronic hepatitis B with HBsAg clearance and nonresponde

123 Patients were divided into three groups: chronic hepatitis B without cirrhosis; HBV-related cirrh

124 ablish a persistent infection in people with chronic hepatitis B, leading to accelerated progression

125 In patients with chronic hepatitis B, TAF appears to be as effective as T

126 unotherapeutic strategy for the treatment of chronic hepatitis B, the efficiencies were not adequate

127 reactivation after liver transplantation for chronic hepatitis B, with a durable HBsAg seroclearance

128 ferent disease phases of young patients with chronic hepatitis B, with emphasis on the so-called immu

129 f serum samples from patients with acute and chronic hepatitis B.

130 of off-NA VR in patients with HBeAg-negative chronic hepatitis B.

131 patients with hepatitis B e antigen-negative chronic hepatitis B.

132 st controversial topics in the management of chronic hepatitis B.

133 shed nucleotide analogue in the treatment of chronic hepatitis B.

134 offer a potential new treatment strategy for chronic hepatitis B.

135 on, but limited data exist for patients with chronic hepatitis B.

136 ay be a good alternative to TDF for treating chronic hepatitis B.

137 sign of curative antiviral therapies against chronic hepatitis B.

138 and foreseeable therapeutic developments in chronic hepatitis B.

139 diseases, which may open a new venue to cure chronic hepatitis B.

140 foreign-born African Americans (FBAAs) with chronic hepatitis B.

141 on of antiviral therapeutics for the cure of chronic hepatitis B.

142 As a positive control, transmission of chronic hepatitis before and after implementation of hep

143 Patients with chronic hepatitis C (CHC) exhibit reduced work productiv

144 mproving prediction of treatment outcomes in chronic hepatitis C (CHC) genotype 4 (G4) is necessary t

145 In resource-rich countries, chronic hepatitis C (CHC) infection is associated with a

146 Liver mortality among individuals with chronic hepatitis C (CHC) infection is common, but the r

147 supplementation on serum fibrotic markers in chronic hepatitis C (CHC) patients.

148 pe of hepatitis C virus (HCV) treatment, but chronic hepatitis C (CHC) remains a leading indication f

149 about mortality rates (MRs) in patients with chronic hepatitis C (CHC) with cirrhosis is limited.

150 hort of 4,172 patients, including 3,129 with chronic hepatitis C (CHC), 555 with chronic hepatitis B

151 epatitis C virus (HCV) is a leading cause of chronic hepatitis C (CHC), liver cirrhosis, and hepatoce

152 t hepatitis C virus (HCV) infection leads to chronic hepatitis C (CHC), which often progresses to liv

153 play important roles in the pathogenesis of chronic hepatitis C (CHC).

154 actors influence liver damage progression in chronic hepatitis C (CHC).

155 We performed a cross-sectional study of chronic hepatitis C (cHCV) patients using tetramer-assoc

156 f Ledipasvir/Sofosbuvir for the treatment of chronic hepatitis C (HCV) includes the truncation of the

157 Patients with chronic hepatitis C (HCV) infection have high prevalence

158 n in retrospective analyses of patients with chronic hepatitis C (HCV).

159 liver damage, especially in individuals with chronic hepatitis C (HCV); however, the impact of nonhea

160 This study included 252 patients with chronic hepatitis C and 150 healthy volunteers.

161 onsistent with these findings, patients with chronic hepatitis C and nonalcoholic steatohepatitis sig

162 can capture nonlinear disease progression in chronic hepatitis C and thus outperform baseline models.

163 Chronic hepatitis C can result in progressive liver dise

164 ntial Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand.

165 terferon (PEG-IFN)-alpha in the treatment of chronic hepatitis C has led to an increase in sustained

166 ive models of risk of disease progression in chronic hepatitis C have limited accuracy.

167 Compared with other countries, patients with chronic hepatitis C infection in Japan tend to be older,

168 ould suggest a secondary Mooren ulcer, but a chronic hepatitis C infection was detected.

169 of hepatitis and fibrosis progression during chronic hepatitis C infection, while contrasting results

170 diseased livers explanted from patients with chronic hepatitis C infection.

171 eks is highly effective for the treatment of chronic hepatitis C infection.

172 ith sickle cell disease are at high risk for chronic hepatitis C infection.

173 mbined cohort of non-cirrhotic patients with chronic hepatitis C or alcoholic liver disease (n = 1121

174 The treatment of chronic hepatitis C patients before they developed cirrh

175 This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment e

176 Additionally, 3150 (59.1%) chronic hepatitis C patients were immune or vaccinated a

177 Among 5328 chronic hepatitis C patients, 2998 (56.3%) were immune o

178 atosteatosis, a common pathology observed in chronic hepatitis C patients.

179 Chronic hepatitis C viral (HCV) infection has been assoc

180 ced hepatocellular carcinoma and concomitant chronic hepatitis C viral infection.

181 ith hepatocellular carcinoma and concomitant chronic hepatitis C viral infection.

182 Rates of hospitalization due to chronic hepatitis C virus (HCV) are increasing in Canada

183 Many patients with chronic hepatitis C virus (HCV) are on prolonged proton-

184 ring nonalcoholic steatohepatitis (NASH) and chronic hepatitis C virus (HCV) compared to alcohol live

185 proved in the United States for treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infecti

186 proved in the United States for treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infecti

187 hase 3 study in previous non-responders with chronic hepatitis C virus (HCV) genotype 1 infection and

188 Interferon-free treatment of chronic hepatitis C virus (HCV) genotype 1 infection may

189 virin in treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection.

190 tions are rapidly evolving for patients with chronic hepatitis C virus (HCV) genotype 1b (GT1b) infec

191 BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) genotype 2 have high rat

192 ermine the optimal regimen for patients with chronic hepatitis C virus (HCV) genotype 2, 3, 4, or 6 i

193 rect-acting antiviral agents that can cure a chronic hepatitis C virus (HCV) infection after 8-12 wee

194 Treatment of chronic hepatitis C virus (HCV) infection after renal al

195 ng evidence indicates an association between chronic hepatitis C virus (HCV) infection and B-cell lym

196 ns are needed for treatment of patients with chronic hepatitis C virus (HCV) infection and cirrhosis.

197 previr regimen for 12 weeks in patients with chronic hepatitis C virus (HCV) infection and stage 4-5

198 ole of MAIT cells in livers of patients with chronic hepatitis C virus (HCV) infection and their fate

199 Patients with cirrhosis resulting from chronic hepatitis C virus (HCV) infection are at risk of

200 trials have demonstrated that patients with chronic hepatitis C virus (HCV) infection associated HCC

201 Chronic hepatitis C virus (HCV) infection causes inducti

202 An unbiased genome-to-genome analysis in chronic hepatitis C virus (HCV) infection confirms the i

203 Whether chronic hepatitis C virus (HCV) infection decreases humo

204 direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstra

205 BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) infection have high rate

206 nd: Use of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infection in kidney tran

207 Use of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infection in kidney tran

208 interferon- and ribavirin-free treatment for chronic hepatitis C virus (HCV) infection in patients co

209 Chronic hepatitis C virus (HCV) infection in patients wi

210 Chronic hepatitis C virus (HCV) infection is a global he

211 BACKGROUND & AIMS: Chronic hepatitis C virus (HCV) infection is a major bur

212 , interferon-alpha (IFN-alpha) treatment for chronic hepatitis C virus (HCV) infection is an ideal mo

213 Chronic hepatitis C virus (HCV) infection is associated

214 Chronic hepatitis C virus (HCV) infection is associated

215 A key question in care of patients with chronic hepatitis C virus (HCV) infection is beginning t

216 Chronic hepatitis C virus (HCV) infection is characteriz

217 The efficacy of antiviral treatment for chronic hepatitis C virus (HCV) infection is determined

218 Treatment for chronic hepatitis C virus (HCV) infection is evolving fr

219 Chronic hepatitis C virus (HCV) infection is more preval

220 The mechanism of how chronic hepatitis C virus (HCV) infection leads to such

221 e status in liver and blood of patients with chronic hepatitis C virus (HCV) infection long after the

222 th human immunodeficiency virus (HIV) and/or chronic hepatitis C virus (HCV) infection may be prescri

223 Chronic hepatitis C virus (HCV) infection may progress t

224 In Egypt, chronic hepatitis C virus (HCV) infection occurs in arou

225 ere are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients wh

226 The immuno-pathogenic mechanisms of chronic hepatitis C virus (HCV) infection remain to be e

227 Diagnosis of chronic hepatitis C virus (HCV) infection requires both

228 Chronic hepatitis C virus (HCV) infection with advanced

229 Treatment of chronic hepatitis C virus (HCV) infection with direct-ac

230 ee, complete regimen for adult patients with chronic hepatitis C virus (HCV) infection without cirrho

231 ting antivirals (DAAs) effectively eradicate chronic hepatitis C virus (HCV) infection, although HCV

232 Fibrosis is associated with chronic hepatitis C virus (HCV) infection, although the

233 have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more effi

234 to a high cure rate in treated patients with chronic hepatitis C virus (HCV) infection, but this stil

235 course of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, we examined t

236 f viral eradication to >90% in patients with chronic hepatitis C virus (HCV) infection.

237 egimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection.

238 and poor physical health among patients with chronic hepatitis C virus (HCV) infection.

239 n associated with liver fibrosis severity in chronic hepatitis C virus (HCV) infection.

240 ) play a central role in the pathogenesis of chronic hepatitis C virus (HCV) infection.

241 egimens have been approved for children with chronic hepatitis C virus (HCV) infection.

242 All patients with chronic hepatitis C virus (HCV) infections can and shoul

243 nterferon-free regimens for the treatment of chronic hepatitis C virus (HCV) infections require furth

244 e direct-acting antivirals (DAA) in treating chronic hepatitis C virus (HCV) is limited by low screen

245 The optimal retreatment strategy for chronic hepatitis C virus (HCV) patients who fail direct

246 In nontransplant patients with chronic hepatitis C virus (HCV), HCV genotype has been l

247 the risk of chronic kidney disease (CKD) in chronic hepatitis C virus (HCV)-infected patients and th

248 We prospectively evaluated 251 chronic hepatitis C virus (HCV)-infected subjects (31% h

249 ed risk of hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV).

250 evir + TMC647055/ritonavir + JNJ-56914845 in chronic hepatitis C virus genotype (GT)1-infected treatm

251 ment for 6 weeks or less among patients with chronic hepatitis C virus genotype 1 infection.

252 afe and highly effective in adolescents with chronic hepatitis C virus genotype 2 or 3 infection.

253 ns with or without ribavirin as treatment of chronic hepatitis C virus in solid organ transplant reci

254 Chronic hepatitis C virus infection activates an intrahe

255 Children with chronic hepatitis C virus infection have limited treatme

256 -acting antiviral drugs for the treatment of chronic hepatitis C virus infection have reduced mortali

257 pulations after DAA therapy in patients with chronic hepatitis C virus infection in the context of th

258 Chronic hepatitis C virus infection is associated with s

259 Chronic hepatitis C virus infection is well-recognized a

260 ffective and well tolerated in patients with chronic hepatitis C virus infection, including those wit

261 nse (SVR) to interferon-based treatments for chronic hepatitis C virus infection, whereas Asian race

262 ent has revolutionized care of patients with chronic hepatitis C virus infection.

263 direct-acting antiviral drugs used to treat chronic hepatitis C virus infection.

264 le degree of liver fibrosis in patients with chronic hepatitis C virus prohibiting cadaveric renal tr

265 acting antiviral agents for the treatment of chronic hepatitis C virus that have significantly increa

266 recommendations on the care of patients with chronic hepatitis C virus who have achieved SVR.

267 lular carcinoma was overrepresented, whereas chronic hepatitis C was underrepresented, in reported Un

268 s B vaccination among patients in China with chronic hepatitis C who are not in treatment.

269 Despite effective treatment for chronic hepatitis C, deficiencies in diagnosis and acces

270 n-free, direct-acting antiviral treatment of chronic hepatitis C, subjects who received ribavirin had

271 udy, we elucidate the potential link between chronic hepatitis C-associated inflammation and alterati

272 and fibrosis in two cohorts of patients with chronic hepatitis C.

273 USION: FD is more prevalent in patients with chronic hepatitis C.

274 as highlighted by the case of the therapy of chronic hepatitis C.

275 ts for prevention of hepatocarcinogenesis in chronic hepatitis C.

276 Chronic liver diseases (CLDs), due to chronic hepatitis C; hepatitis B; nonalcoholic fatty liv

277 ost infected patients, and eventually causes chronic hepatitis, cirrhosis, and hepatocellular carcino

278 ons of people worldwide and causes acute and chronic hepatitis, cirrhosis, and hepatocellular carcino

279 is a major cause of liver diseases, such as chronic hepatitis, cirrhosis, and hepatocellular carcino

280 s (HCV) infection, we analyzed data from the Chronic Hepatitis Cohort Study (CHeCS), a large U.S. obs

281 arge healthcare systems participating in the Chronic Hepatitis Cohort Study (CHeCS).

282 B patients followed during 2006-2013 in the Chronic Hepatitis Cohort Study, 78% had >/=1 alanine ami

283 B in chronic hepatitis patients from the US Chronic Hepatitis Cohort Study.

284 on therapy to ribavirin for the treatment of chronic hepatitis E in immunocompromised patients.

285 Chronic hepatitis E virus (HEV) infection is a significa

286 Antiviral treatment options for chronic Hepatitis E Virus (HEV) infections are limited a

287 -four solid-organ-transplant recipients with chronic hepatitis E virus (HEV) infections were given ri

288 Ribavirin is efficient at treating chronic hepatitis E virus infection in solid-organ trans

289 e patients with a solid-organ transplant and chronic hepatitis E virus infection were given ribavirin

290 in developing effective therapeutics against chronic hepatitis E.

291 h hepatitis E virus genotype 3 may result in chronic hepatitis in immunocompromised patients.

292 gnant women and has been recognized to cause chronic hepatitis in immunocompromised populations.

293 Liver fibrosis can regress in patients with chronic hepatitis in whom the underlying cause of liver

294 virus (HCV) is one of the leading causes of chronic hepatitis, liver cirrhosis and hepatocellular ca

295 Hepatitis C virus (HCV) is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular c

296 and vaccination against hepatitis A and B in chronic hepatitis patients from the US Chronic Hepatitis

297 tolerance to hepatocellular Ags, leading to chronic hepatitis resembling human AIH type 1.

298 s C virus (HCV) have ushered in a new era in chronic hepatitis treatment.

299 trast, HBV-infected HIS-HUHEP mice developed chronic hepatitis with 10-fold lower titers and antigen-

300 its DNA and infection can lead to acute and chronic hepatitis with a high risk of liver cirrhosis an